Literature DB >> 8673525

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.

A Bolmstedt1, S Sjölander, J E Hansen, L Akerblom, A Hemming, S L Hu, B Morein, S Olofsson.   

Abstract

One of the functions of N-linked glycans of viral glycoproteins is protecting otherwise accessible neutralization epitopes of the viral envelope from neutralizing antibodies. The aim of the present study was to explore the possibility to obtain a more broadly neutralizing immune response by immunizing guinea pigs with gp160 depleted of three N-linked glycans in the CD4-binding domain by site-directed mutagenesis. Mutant and wild type gp160 were formulated into immunostimulating complexes and injected s.c. into guinea pigs. Both preparations induced high serum antibody response to native gp120 and V3 peptides. Both preparations also induced antibodies that bound equally well to the V3 loop or the CD4-binding region, as determined by a competitive enzyme-linked immunosorbent assay (ELISA). The sera from animals, immunized with mutated glycoprotein, did not neutralize nonrelated HIV strains better than did sera from animals, immunized with wild type glycoprotein. Instead, a pattern of preferred homologous neutralization was observed, i.e., sera from animals, immunized with mutant gp160, neutralized mutant virus better than wild type virus, and vice versa. These data indicated that elimination of the three N-linked glycans from gp160 resulted in an altered local antigenic conformation but did not uncover hidden neutralization epitopes, broadening the immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673525     DOI: 10.1097/00042560-199607000-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  31 in total

1.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.

Authors:  S Surman; T D Lockey; K S Slobod; B Jones; J M Riberdy; S W White; P C Doherty; J L Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

5.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 6.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 7.  Current advances and challenges in HIV-1 vaccines.

Authors:  Isaac R Rodriguez-Chavez; Mary Allen; Edgar L Hill; Rebecca L Sheets; Michael Pensiero; James A Bradac; M Patricia D'Souza
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

8.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

9.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Authors:  Eloìsa Yuste; Jacqueline Bixby; Jeffrey Lifson; Shuji Sato; Welkin Johnson; Ronald Desrosiers
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.